報價延遲最少15分鐘:2024/12/23 22:23 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.3737 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.20/-0.12
|
|
企業價值
29.57M
|
| 資產負債 |
|
每股賬面淨值
0.10
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
1.35M
|
|
每股收益
0.02
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/23 22:23 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps. |